By testing serial dilutions of tumor DNA samples with Tier I/II variants (BRAF V600E, KRAS G12C, and EGFR exon 19 deletion p.L747_E749del), the LOD for accurate and reproducible variant calling was determined to be 5% of variant allele frequency. Here, KRAS is linked to neoplasm.